Costly and Long Drug Development Process Driving Organ-on-Chip Industry
The major drivers for the organ-on-chip market are government funding and support, increasing demand for the discovery and development of effective drugs, concerns with respect to drug testing on animals, and rise in the number of drug repurpose approaches. Generating a revenue of $11.0 million in 2017, the sales of such products are expected to value $163.1 million by 2025, witnessing a CAGR of 40.1% during 2018–2025 (forecast period). The term refers to extremely small cell culture chips with microfluidic channels, which simulate the workings of real human cells and tissues.
Download sample copy off this report@ https://www.psmarketresearch.com/market-analysis/organ-on-chip-market/report-sample
When segmented by type, the market is categorized into liver, lung, kidney, heart, intestine, brain, and others; others include bone marrow, artery, blood–brain barrier, and skin. Among these, the liver category dominated the organ-on-chip market in 2017, as a result of the rising cases of hepatic diseases, such as liver cancer, hepatic fibrosis, cirrhosis, and hepatitis, and the need for effective drugs. Even during the forecast period, it is projected to witness the highest CAGR, of 46.1%.
During the forecast period, the drug discovery division would experience the fastest growth in the organ-on-chip market, at a CAGR of 47.7%, as the current process consumes a lot of time and effort and carries a high failure rate. The new technology provides faster and cost-effective results about the toxicity, efficacy, and pharmacokinetics of the active agents. Additionally, it helps in identifying the drug target and the side effect of the active agent, if any, thereby speeding up the drug development process.
Pre-Purchase Inquiry at@ https://www.psmarketresearch.com/send-enquiry?enquiry-url=organ-on-chip-market
Globally, North America held the largest share in the organ-on-chip market, with the U.S. as the larger revenue contributor, in 2017. This was due to the robust government support for technological research and development (R&D) and heavy investments by major pharma firms in the field. Asia-Pacific (APAC) is expected to witness the fastest progress in the industry, owing to the surging number of government initiative for R&D, escalating healthcare expenditure, and rising usage of advanced technologies.
Hence, as the requirement for cost-effective and fast drug delivery process increases, so would the adoption of organ-on-chips.
